Abstract: Provided is an oil deterioration diagnosis device capable of detecting oil deterioration accurately and early in real time during operation of an operating machine without oil sampling. An oil deterioration diagnosis device 10 for a construction machine including an oil hydraulic circuit 1 includes: a floodlight projector 11a configured to irradiate oil flowing through the oil hydraulic circuit 1 with measuring light having a predetermined wave number or wavelength during operation of the construction machine; a photoreceiver 11b configured to receive transmitted light having penetrated the oil; a signal processing unit 11c configured to continuously or intermittently measure absorbance or transmittance; and a diagnosis unit 12 configured to detect a decrease of an antioxidant contained in the oil or an increase of a peroxide contained in the oil, based on changes in the absorbance or the transmittance.

Abstract: To achieve stable administration of a medicine into a dermis by improving the operability of a device that inserts a microneedle into a skin. An impacting type applicator (1) for a microneedle patch is an applicator that applies a microneedle patch (3) to a skin includes a main body (5), a spring expanding/compressing lever (7), a resilient body (9), a lock mechanism (11), and a piercing switch (13). The spring expanding/compressing lever (7) is movably attached to the main body (5), and the microneedle patch (3) can be attached to a leading end of the spring expanding/compressing lever (7). The resilient body (9) is a member that imparts a biasing force to the spring expanding/compressing lever (7). The lock mechanism (11) is a mechanism that locks the spring expanding/compressing lever (7) in a state where the resilient body (9) exerts the biasing force on the main body (5).

Abstract: A product having a microneedle array is provided wherein the composition distribution has been adjusted with good accuracy. A droplet-delivery apparatus of a microneedle-array manufacturing apparatus is configured capable of delivering, to each recessed part, droplets of a raw-material liquid in a prescribed amount that is less than the capacity of the recessed part. An aligning apparatus can align the relative position of the droplet-delivery apparatus and a mold such that the droplets from the droplet-delivery apparatus are caused to land in each of the recessed parts. The droplet-delivery apparatus delivers a plurality of the droplets to each of the recessed parts; and the aligning apparatus aligns the relative position of the droplet-delivery apparatus and the mold such that a second droplet lands in each of the recessed parts on the center part side of a first droplet.

Abstract: The invention is a microneedle preparation administration apparatus comprising: a guide tube; a pedestal in which at least a part thereof including a front end surface is housed within the guide tube and slides in length direction; and driving means for driving the pedestal toward a front end part of the guide tube, and microneedle preparations being to be attached to the front end surface of the pedestal.

Abstract: To achieve stable administration of a medicine into a dermis by improving the operability of a device that inserts a microneedle into a skin. An impacting type applicator (1) for a microneedle patch is an applicator that applies a microneedle patch (3) to a skin includes a main body (5), a spring expanding/compressing lever (7), a resilient body (9), a lock mechanism (11), and a piercing switch (13). The spring expanding/compressing lever (7) is movably attached to the main body (5), and the microneedle patch (3) can be attached to a leading end of the spring expanding/compressing lever (7). The resilient body (9) is a member that imparts a biasing force to the spring expanding/compressing lever (7). The lock mechanism (11) is a mechanism that locks the spring expanding/compressing lever (7) in a state where the resilient body (9) exerts the biasing force on the main body (5).

Abstract: An object of the present invention is to provide a microneedle and a method for producing the same that are specialized for individual treatment purposes and can efficiently achieve a treatment effect. The microneedle according to the present invention relates to a microneedle including a drug containing layer, an intermediate layer, and a base layer in order from a tip side, wherein a boundary between the drug containing layer and the intermediate layer has a shape protruding toward the intermediate layer, and a thickness of a central portion of the intermediate layer is smaller than a thickness of a peripheral edge portion. The microneedle according to the present invention can be more easily broken in the intermediate layer than the conventional microneedle, thereby allowing the drug containing layer to be placed to properly target a particular area in epidermis or dermis.

Abstract: An object of the present invention is to solve problems of microneedles produced by conventional methods, and provide a microneedle with improved penetrability and shape retainability. A conical microneedle (10) includes a tip part (2) containing a drug and biodegradable polymer, and a base part (4) that does not contain drug, a tip (1) side is formed as a tip-reinforced region (6), a base (3) side adjacent to the tip-reinforced region with or without coating to the tip art of the microneedle(6) is formed as a non-reinforced region (7), and a hardness of the tip-reinforced region (6) is higher than the hardness of the non-reinforced region (7). A microneedle patch including the microneedle (10) according to the present invention can reduce pressing strength on application to a patient, and alleviate pain and fear to the patient.

Abstract: A microneedle patch with which a treatment is reliably completed in a short time when a microneedle is administered into skin or mucous membrane is provided. A microneedle patch (100F) includes a base member (101) and a plurality of microneedles (103g) supported by the base member (101). Each microneedle (103g) includes a top-section layer (104) comprising a biologically active substance to be inserted in dermis (310), and an intermediate layer (106) provided between the top-section layer (104) and the base member (101), having a composition having breaking strength weaker than breaking strength of a composition of the top-section layer (104), and having a thickness of 5 ?m and 100 ?m inclusive.

Abstract: A product having a microneedle array is provided wherein the composition distribution has been adjusted with good accuracy. A droplet-delivery apparatus of a microneedle-array manufacturing apparatus is configured capable of delivering, to each recessed part, droplets of a raw-material liquid in a prescribed amount that is less than the capacity of the recessed part. An aligning apparatus can align the relative position of the droplet-delivery apparatus and a mold such that the droplets from the droplet-delivery apparatus are caused to land in each of the recessed parts. The droplet-delivery apparatus delivers a plurality of the droplets to each of the recessed parts; and the aligning apparatus aligns the relative position of the droplet-delivery apparatus and the mold such that a second droplet lands in each of the recessed parts on the center part side of a first droplet.

Abstract: A problem to be solved of the present invention is to provide a drug formulation and a method of administering an active ingredient which allow the active ingredient to be delivered evenly into the site of action in the skin with high efficiency while ensuring stability of the active ingredient over a long time, and which are easily handled and are less stressful for patients. Mean for solving the problem is a microneedle assembly formulation for skin treatment comprising a platform and a plurality of conical or pyramidal microneedles formed on the platform containing a base composed of a bio-soluble and thread-forming polymer substance and an objective substance retained in the base, wherein the objective substance is a substance effective for prevention or treatment of skin senescence, or treatment of skin scar.

Abstract: The invention is a microneedle preparation administration apparatus comprising: a guide tube; a pedestal in which at least a part thereof including a front end surface is housed within the guide tube and slides in length direction; and driving means for driving the pedestal toward a front end part of the guide tube, and microneedle preparations being to be attached to the front end surface of the pedestal.

Abstract: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.

Abstract: The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or immunocytological assay methods, and kits for determining the expression level of CLCP1 in cells or tissues, all of which use the antibodies; pharmaceutical compositions comprising the antibodies; agents for treating or preventing CLCP1-expressing cancer; agents for inhibiting growth, migration, invasion, or metastasis of CLCP1-expressing cancer cells; immunostaining agents for staining CLCP1-expressing cancer cells; and agents for treating or preventing CLCP1-expressing tumor.

Abstract: The present invention provides a method for testing mesothelioma comprising a step of determining a concentration of a human periostin protein in at least one type of sample of blood or pleural fluid of a subject. In the step of determining the concentration of human periostin protein, an antibody directed against human periostin protein may be used. The present invention further provides a kit for diagnosing mesothelioma, said kit comprising an antibody directed against human periostin protein. In the kit for diagnosing mesothelioma, the antibody directed against a human periostin protein may be an antibody that binds to a polypeptide consisting of an amino acid sequence set out in SE ID NO: 2.

Abstract: Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.

Abstract: An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell.

Abstract: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.

Abstract: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.

Abstract: A problem to be solved of the present invention is to provide a drug formulation and a method of administering an active ingredient which allow the active ingredient to be delivered evenly into the site of action in the skin with high efficiency while ensuring stability of the active ingredient over a long time, and which are easily handled and are less stressful for patients. Mean for solving the problem is a microneedle assembly formulation for skin treatment comprising a platform and a plurality of conical or pyramidal microneedles formed on the platform containing a base composed of a bio-soluble and thread-forming polymer substance and an objective substance retained in the base, wherein the objective substance is a substance effective for prevention or treatment of skin senescence, or treatment of skin scar.

Abstract: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.